Sublingual five-grass pollen tablets (Oralair®): a guide to their use as allergen immunotherapy for grass pollen-induced allergic rhinoconjunctivitis
暂无分享,去创建一个
[1] G. Dranitsaris,et al. Sublingual or subcutaneous immunotherapy for seasonal allergic rhinitis: an indirect analysis of efficacy, safety and cost. , 2014, Journal of evaluation in clinical practice.
[2] R. Pawankar,et al. Allergic rhinitis: current options and future perspectives , 2014, Current opinion in allergy and clinical immunology.
[3] J. Bousquet,et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update , 2014, The World Allergy Organization journal.
[4] R. Mösges,et al. PD14 - Non-interventional 2-year study of sublingual immunotherapy in children and adolescents with allergic rhinoconjunctivitis caused by grass pollen , 2014, Clinical and Translational Allergy.
[5] R. Mösges,et al. P85 - Asthmatic children and adolescents treated in daily medical practice – results from a 2-year sublingual allergen immunotherapy (AIT) study with grass pollen tablets , 2014, Clinical and Translational Allergy.
[6] L. Losappio,et al. 5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study , 2013, Journal of asthma and allergy.
[7] H. Malling,et al. Post‐treatment efficacy of discontinuous treatment with 300IR 5‐grass pollen sublingual tablet in adults with grass pollen‐induced allergic rhinoconjunctivitis , 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[8] T. Casale,et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. , 2013, The Journal of allergy and clinical immunology.
[9] A. Cicchetti,et al. Economic Evaluation of 5-Grass Pollen Tablets Versus Placebo in the Treatment of Allergic Rhinitis in Adults , 2013, Clinical Drug Investigation.
[10] L. Klimek,et al. Specific immunotherapy-indications and mode of action. , 2013, Deutsches Arzteblatt international.
[11] T. Casale,et al. Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: the importance of allergen-specific serum IgE. , 2012, The Journal of allergy and clinical immunology.
[12] M. Augustin,et al. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany , 2012, Journal of medical economics.
[13] H. Malling,et al. Post-treatment, Long-term Efficacy Of A 300IR Sublingual Tablet Of 5-grass Pollen Allergen Extract In Adults With Grass Pollen-induced Allergic Rhinoconjunctivitis: The Relationship With Disease Severity , 2012 .
[14] A. Iglesias-Cadarso,et al. Risk factors for systemic reactions to allergen immunotherapy , 2011, Current opinion in allergy and clinical immunology.
[15] C. Rhee,et al. Sublingual immunotherapy in allergic rhinitis , 2011, Asia Pacific allergy.
[16] H. Malling,et al. Rhinitis , sinusitis , and upper airway disease Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen – induced rhinoconjunctivitis , 2011 .
[17] E. Vicaut,et al. The average Adjusted Symptom Score, a new primary efficacy end‐point for specific allergen immunotherapy trials , 2011, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[18] P. Devillier,et al. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy , 2011, Allergy.
[19] J. Bousquet,et al. GA2LEN/EAACI pocket guide for allergen‐specific immunotherapy for allergic rhinitis and asthma , 2010, Allergy.
[20] S. Halken,et al. Five‐grass pollen 300IR SLIT tablets: efficacy and safety in children and adolescents , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[21] Holger J Schünemann,et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. , 2010, The Journal of allergy and clinical immunology.
[22] P. Devillier,et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. , 2009, The Journal of allergy and clinical immunology.
[23] A. Didier,et al. Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[24] H. Malling,et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[25] A. Didier,et al. Agreement of efficacy assessments for five‐grass pollen sublingual tablet immunotherapy , 2009, Allergy.
[26] H. Malling,et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. , 2007, The Journal of allergy and clinical immunology.
[27] J Bousquet,et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce , 2007, Allergy.
[28] P. Kuna,et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. , 2009, The Journal of allergy and clinical immunology.